GM103

AXP000043.1 · Oncolytic virus

Platform
adenovirus
Originator
GeneMedicine Co.
Sponsor
GeneMedicine Co.

Names

NameTypeSource
GM103preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Replication
conditionally replicating
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C208077

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06265025GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid TumorsRecruitingPhase 1/22024-02-202025-05-30125Breast Cancer; Cervical Cancer; Colorectal Cancer; Head and Neck Cancer; Malignant Melanoma; Renal Cell Carcinoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 30703976First Report of Geosmithia morbida on English Walnut and its Paradox Rootstock in California.Plant disease2014name in abstract: GM103

Notes

Korean oncolytic adenovirus; phase I/II NCT06265025, intratumoral, alone and with pembrolizumab. Transgenes and backbone not stated in any source consulted; left empty rather than guessed.

How to cite

GM103 (AXP000043.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000043.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.